In order to achieve a better therapeutic effect, six to eight times of chemotherapy are often needed after early surgery for triple-negative breast cancer, and patients should follow the doctor’s instructions to cooperate with the treatment. Breast cancer is a common malignant tumor in women, mostly caused by heredity and gene mutation. Triple-negative breast cancer means that the patient’s estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 are all negative, which implies that the disease has a higher degree of malignancy and a poorer prognosis. Therefore, in order to achieve better therapeutic effect and reduce the number of recurrence after surgical resection, early stage patients with triple-negative breast cancer are often required to undergo postoperative adjuvant therapy, such as chemotherapy, which is mostly carried out for 6 to 8 times. Commonly used chemotherapeutic drugs include cyclophosphamide, paclitaxel, etc., which should be applied under the guidance of doctors.